QC Kinetix Leads Innovations in Regenerative Medicine, Revolutionizing Healthcare

QC Kinetix has rapidly emerged as a leading regenerative medicine company, offering innovative, non-surgical treatment options for joint pain and discomfort. Since its inception in 2017, QC Kinetix has experienced rapid growth, now serving thousands of patients across over 100 cities nationwide with its advanced, non-invasive therapies.

The company specializes in regenerative treatments that leverage the body’s inherent healing abilities, aiming to improve function and alleviate musculoskeletal pain without resorting to surgery.

In May 2024, QC Kinetix earned a spot in Entrepreneur’s top 10 for the 2024 Top New and Emerging Franchises, ranking ninth. This recognition, up five places from the previous year, highlights the company’s remarkable growth in unit numbers, financial robustness, and brand strength.

Over the past three years, QC Kinetix has achieved a staggering 2,111% growth in units, marking it as one of the top-performing brands in the sector.

“We’re honored to rank among some of the fastest-growing franchise brands,” said the CEO of QC Kinetix. “The recognition is a true testament to our entire team’s hard work and dedication. I’m excited to watch our brand continue to grow and push the boundaries of what’s possible in the regenerative medicine industry.”

QC Kinetix is supported by leading figures in the industry and is steadfast in its mission to offer patients an exceptional alternative for alleviating pain. Motivated by a profound commitment to enhancing life quality without relying on medications, surgeries, or steroids, QC has positively impacted thousands of lives through its innovative biologics treatment protocols.

Recently, the company welcomed Dr. Mitchell Sheinkop, a distinguished orthopedic surgeon, as its national medical director. With over 37 years specializing in joint replacement surgery, Dr. Sheinkop’s engagement marks a new chapter for the company, underscoring his conviction in the revolutionary potential of regenerative medicine and his dedication to patient care.

In his role, Dr. Sheinkop will lead the medical management team, concentrating on refining treatment protocols and spearheading research and development to maintain QC Kinetix’s position at the forefront of medical advancements. His plans include integrating physical therapy and weight management into the treatment plans, aiming to enhance patient outcomes and satisfaction, thereby elevating the brand’s overall impact.

As Dr. Sheinkop takes the helm in this exciting new era for QC Kinetix, his extensive clinical experience combined with his commitment to education and professional development uniquely qualifies him to guide the company towards greater innovation and success.

The company also enjoys support from notable sports personalities, such as Pro Football Hall of Famer Emmitt Smith, who advocates for QC Kinetix as its national spokesperson.

“I’ve got to keep taking care of these joints,” Smith said, “no losing for this guy. When I take QC Kinetix natural supplements, it’s like – bam – Emmitt 2.0. Sometimes, you need a competitive edge.”

What is QC Kinetix?

A medical doctor, a physician assistant, a nurse practitioner, and a business expert convened with a shared vision and a goal to name their budding venture. Drawing inspiration from their base in Charlotte, North Carolina—affectionately called “the Queen City” (QC)—they derived the first part of their business name.

The term Kinetix hints at kinetic energy, which relates to movement. QC Kinetix’s mission is to restore movement in individuals by harnessing the body’s cell regeneration capabilities.

The founders of QC Kinetix saw a pivotal chance to redefine traditional approaches to treating musculoskeletal pain. They pioneered a novel concierge medical model focused on regenerative medicine to enhance patient well-being, marking a departure from conventional pain management strategies. This innovative mindset distinguishes QC Kinetix and fuels their ongoing quest to advance the field of regenerative medicine.

For many patients hindered by pain that affects their daily activities—whether it’s golfing, climbing stairs, or playing with grandchildren—QC Kinetix presents an effective treatment alternative that eschews harmful medications, toxic injections, and surgical risks.

“No longer did we want insurance to tell us what they were willing to pay to treat a patient,” a company spokesperson explained. “We wanted the research to tell us the most effective method, whether it was covered by insurance or not, and bring it to the United States in a very transparent and patient-focused manner. QC Kinetix is an opportunity to become the first option when dealing with pain, not the alternative to those ways. That is our mission over time.”

QC Kinetix emphasizes a patient-focused approach in its treatments. As a pioneer in regenerative medicine, the company enhances the active lifestyles of individuals by offering comprehensive treatments for musculoskeletal and joint pain through regenerative medicine.

The clinic has effectively helped thousands of patients with its distinctive biologics treatment protocols. Utilizing the body’s inherent healing mechanisms, QC Kinetix provides cutting-edge natural biologic therapies as alternatives to invasive surgeries and reliance on pain medications.

Dedicated to optimizing the body’s natural repair and healing capabilities from within, the clinics aim to significantly enhance function and overall life quality.

Patients often seek treatment for pain in areas such as the knees, shoulders, or hips. QC Kinetix leverages the body’s own properties to foster health regeneration. The company has achieved numerous milestones since its inception.

By 2023, QC Kinetix surpassed $100 million in system-wide sales, and in April 2024, it celebrated treating its 40,000th patient amid its national expansion that started in 2021.

“It is our goal to change medicine,” the CEO of QC Kenetix shared. “We want to be the first thing people think about when they or a loved one are dealing with pain. We measure that success by seeing feedback from our patients that we could change their lives. We aim to care for our patients and employees first, knowing that growth and profit will follow.”

QC Kinetix is poised on the brink of a significant breakthrough.

Having established a solid presence in the United States, QC Kinetix is now eyeing expansion into international markets. The brand has ambitious plans to venture into the United Kingdom, Australia, and New Zealand in the upcoming years, aiming to reinforce its status as a global frontrunner in regenerative medicine.

The company targets opening 250 locations across the United States by the end of 2024.

Despite only four years in the franchising market, the rapid growth of QC Kinetix is noteworthy. The CEO of QC Kinetix expressed that the only unexpected aspect of the company’s expansion is that it hasn’t happened more swiftly, given the strong demand for alternatives to pain medications and surgeries. This growth underscores the substantial consumer interest in non-surgical pain relief options and the keen attention from franchise investors and operators in the medical field.

“I love this brand and our future,” the CEO of QC Kinetix said.. “It’s about impacting people’s lives and being a game-changer in the medical field.”